Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)
Inhibikase Therapeutics (IKT) reported Change in Receivables of -$79602.0 for Q3 2023, down 1191.93% year-over-year from $7290.0 in Q3 2022, and down 627.76% quarter-over-quarter from $15083.0 in Q2 2023.
Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 3 years of Change in Receivables data on file, last reported at -$79602.0 in Q3 2023.
- Change in Receivables for Q3 2023 came in at -$79602.0, down 1191.93% year-over-year; the trailing twelve-month figure through Jun 2024 was -$79602.0 (down 143.45% YoY), and the FY2023 annual result was -$39881.0, down 200.0% from the prior year.
- Change in Receivables slipped to -$79602.0 in Q3 2023 per IKT's latest filing, from $15083.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $332774.0 in Q1 2021 and troughed at -$369099.0 in Q3 2021.
- A 3-year average of $10012.8 and a median of $7290.0 in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables surged 226.87% in 2022, then tumbled 1191.93% in 2023.
- A 3-year view of Change in Receivables shows it stood at -$107341.0 in 2021, then surged by 226.87% to $136180.0 in 2022, then sank by 158.45% to -$79602.0 in 2023.
- Business Quant data shows IKT's Change in Receivables at -$79602.0 in Q3 2023, $15083.0 in Q2 2023, and $24638.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -79,602.00 |
| Sep 30, 2023 | -79,602.00 |
| Jun 30, 2023 | 15,083.00 |
| Jun 30, 2023 | 15,083.00 |
| Mar 31, 2023 | 24,638.00 |
| Mar 31, 2023 | 24,638.00 |
| Dec 31, 2022 | 136,180.00 |
| Dec 31, 2022 | 136,180.00 |
| Sep 30, 2022 | 7,290.00 |
| Sep 30, 2022 | 7,290.00 |
| Jun 30, 2022 | -41,424.00 |
| Jun 30, 2022 | -41,424.00 |
| Mar 31, 2022 | -62,165.00 |
| Mar 31, 2022 | -62,165.00 |
| Dec 31, 2021 | -107,341.00 |
| Dec 31, 2021 | -107,341.00 |
| Sep 30, 2021 | -369,099.00 |
| Sep 30, 2021 | -369,099.00 |
| Jun 30, 2021 | 253,807.00 |
| Jun 30, 2021 | 253,807.00 |